Samsung eyes biotech investments via Flagship Pioneering

Three Samsung Group units will invest in Flagship Pioneering's portfolio companies through their second life science fund

The interior of a Samsung Biologics plant
The interior of a Samsung Biologics plant
Jeong Min Nam 2
2024-01-09 13:27:03 peux@hankyung.com
Bio & Pharma

Samsung C&T Corp., Samsung Biologics Co. and Samsung Bioepis Co. will ramp up investments in US biotechnology startups in collaboration with Flagship Pioneering, a US venture capital firm, Samsung C&T said on Tuesday.

Samsung C&T has signed a memorandum of understanding with Flagship Pioneering. Under the agreement, the investment firm will tap the second life science fund launched by the three Samsung companies for future investments, while its portfolio companies collaborate with Samsung Group arms.

The fund size has not been disclosed.

“We look forward to expanding early investment opportunities in future biotechnology companies that change the world,” Kim Jaywoo, executive vice president at Samsung C&T, said in a statement.

In August 2022, Samsung invested $150 million in Senda Biosciences, a portfolio company of Flagship Pioneering, via its first life science fund.

Samsung eyes biotech investments via Flagship Pioneering

“Through this collaboration, Samsung will work alongside Flagship-founded companies, leveraging Samsung’s leading technologies and capabilities to accelerate first and best-in-class therapies,” Flagship Pioneering said in a separate statement.

They will team up to develop translational medicine and access to high-quality clinical samples, while leveraging Samsung’s clinical trials infrastructure.

“The collaboration between Samsung and Flagship leverages the expertise of both organizations in the areas of life science technology, artificial intelligence, and CDMO services and extends across Flagship’s ecosystem of companies,” Flagship Pioneering added.

CDMO stands for a contract development and manufacturing organization.

Samsung eyes biotech investments via Flagship Pioneering

Flagship Pioneering has invested in 165 companies. In 2010, it established Moderna Inc., which has developed a COVID-19 vaccine.

Samsung Biologics, a CDMO, has produced the Moderna COVID-19 vaccine since October 2021.

“We look forward to seeing the accelerating effect of Samsung’s various technical expertise and extensive commercial capabilities on the future innovations Flagship and its ecosystem of companies will bring to market,” Samsung’s Kim was quoted as saying in the Flagship statement.

Write to Jeong Min Nam at peux@hankyung.com
 

Yeonhee Kim edited this article. 

Samsung Biologics eyes new drugmaker acquisitions

Samsung Biologics eyes new drugmaker acquisitions

Samsung Biologics President & CEO John Rim (left) greets a visitor to its booth at CPHI Worldwide 2023, a global bio and pharmaceutical conference, in Barcelona on Oct. 25, 2023 (Courtesy of Samsung Biologics) BARCELONA -- Samsung Biologics Co., the world’s top contract manufacturing

Samsung Biologics partners with Europe's largest VC

Samsung Biologics partners with Europe's largest VC

Samsung Biologics Co., the world's largest contract drug manufacturer, announced on Tuesday it has teamed up with global biotech venture capitalist (VC) Kurma Partners.Under this agreement, Samsung Biologics will provide customized contract development services for biotech companies that Kurma

Samsung Bioepis seeks to buy Biogen biosimilar unit

Samsung Bioepis seeks to buy Biogen biosimilar unit

Researcher at Samsung Bioepis' laboratory (Courtesy of Samsung) Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea’s Samsung Group, seeks to buy a biosimilar business division of Nasdaq-listed Biogen Inc. at less than 1 trillion won ($775.3 million),

Samsung Bioepis enters US market for biosimilars of Humira

Samsung Bioepis enters US market for biosimilars of Humira

South Korea's biopharmaceutical company Samsung Bioepis, which was expected to struggle on the US market for biosimilars of Humira, the world's top-selling treatment for autoimmune diseases such as rheumatoid arthritis, has received a major boost in this venture.Prime Therapeutics, the No. 5 P

Korea approves export of Samsung Biologics-made Moderna vaccine

Korea approves export of Samsung Biologics-made Moderna vaccine

Samsung Biologics drug product manufacturing process (Courtesy of Samsung Biologics) South Korea approved exports of Moderna Inc.’s COVID-19 vaccine produced by Samsung Biologics Co. in a move that will help the country’s largest conglomerate Samsung Group accelerate the development

Samsung Biologics to make Moderna’s mRNA vaccine from Q3

Samsung Biologics to make Moderna’s mRNA vaccine from Q3

South Korea-US vaccine partnership event held in Washington D.C. May 22 (From left: Samsung Biologics CEO John Rim, South Korean President Moon Jae-in, Moderna CEO Stéphane Bancel) Samsung Biologics Co. will be manufacturing the US company Moderna’s COVID-19 vaccine (mRNA-1273) fro

(* comment hide *}